About Paul Friel
Paul Friel is executive vice president of corporate operations at Catalyst Pharmaceuticals, an Angelini Pharma company. He joined Catalyst in 2024 as a consultant and took the executive role in January 2026. He oversees market access, patient services and commercial operations. His group also covers analytics, project management, new product planning and information technology. He is also a director of 28bio and Herald Therapeutics. On October 28, 2026, Vergent Bioscience, a clinical-stage biotech company working on targeted imaging during surgery, named him to its board of directors.
Earlier, he was chief commercial officer at Elevar Therapeutics and at BeyondSpring Pharmaceuticals. He was also president and general manager of Takeda Canada. He spent most of his career at TAP, Abbott and Takeda. He has worked in commercial and business development roles for over 30 years. He holds a bachelor of science in business administration from Kansas State University. His MBA is from the University of Kansas Graduate School of Business.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Paul Friel in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Paul Friel works with at each company, as listed on that company's latest Form D.
